91 related articles for article (PubMed ID: 25443887)
1. Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia.
Kempf E; Hirsch P; Labopin M; Viguié F; Isnard F; Tang R; Marzac C; Marie JP; Mohty M; Legrand O
Leuk Res; 2014 Dec; 38(12):1425-9. PubMed ID: 25443887
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
Wenzell CM; Gallagher EM; Earl M; Yeh JY; Kusick KN; Advani AS; Kalaycio ME; Mukherjee S; Tiu RV; Maciejewski JP; Sekeres MA
Am J Hematol; 2013 Oct; 88(10):906-9. PubMed ID: 23828018
[TBL] [Abstract][Full Text] [Related]
3. Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.
Tavitian S; Denis A; Vergez F; Berard E; Sarry A; Huynh A; Delabesse E; Luquet I; Huguet F; Récher C; Bertoli S
Am J Hematol; 2016 Feb; 91(2):193-8. PubMed ID: 26509505
[TBL] [Abstract][Full Text] [Related]
4. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
5. [The Relationship between Body Mass Index and Adult Acute Myeloid Leukemia].
Wang YN; Wei T; Xi YM; Yang MY; Niu L; Wang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):677-684. PubMed ID: 34105456
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
8. A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia.
Crysandt M; Kramer M; Ehninger G; Bornhäuser M; Berdel WE; Serve H; Röllig C; Kaifie A; Jost E; Brummendorf TH; Wilop S
Eur J Haematol; 2016 Jul; 97(1):17-24. PubMed ID: 26277604
[TBL] [Abstract][Full Text] [Related]
9. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
12. Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.
Cahu X; Carré M; Recher C; Pigneux A; Hunault-Berger M; Vey N; Chevallier P; Delaunay J; Gyan E; Lioure B; Bonmati C; Himberlin C; Hicheri Y; Guillerm G; Didier B; Larosa F; Ojeda-Uribe M; Bernard M; Bene MC; Ifrah N; Cahn JY
Eur J Haematol; 2017 May; 98(5):443-449. PubMed ID: 28122150
[TBL] [Abstract][Full Text] [Related]
13. Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
Harada K; Doki N; Hagino T; Miyawaki S; Ohtake S; Kiyoi H; Miyazaki Y; Fujita H; Usui N; Okumura H; Miyamura K; Nakaseko C; Fujieda A; Nagai T; Yamane T; Sakamaki H; Ohnishi K; Naoe T; Ohno R; Ohashi K
Ann Hematol; 2018 Jan; 97(1):73-81. PubMed ID: 29196987
[TBL] [Abstract][Full Text] [Related]
14. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
15. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
16. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
[TBL] [Abstract][Full Text] [Related]
17. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.
Sengsayadeth SM; Jagasia M; Engelhardt BG; Kassim A; Strickland SA; Goodman S; Lucid C; Vnencak-Jones CL; Greer JP; Savani BN
Bone Marrow Transplant; 2012 Dec; 47(12):1535-7. PubMed ID: 22659680
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
19. Reasons for treating secondary AML as de novo AML.
Ostgård LS; Kjeldsen E; Holm MS; Brown Pde N; Pedersen BB; Bendix K; Johansen P; Kristensen JS; Nørgaard JM
Eur J Haematol; 2010 Sep; 85(3):217-26. PubMed ID: 20456491
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
Ornstein MC; Mukherjee S; Mohan S; Elson P; Tiu RV; Saunthararajah Y; Kendeigh C; Advani A; Kalaycio M; Maciejewski JP; Sekeres MA
Am J Hematol; 2014 Feb; 89(2):168-73. PubMed ID: 24123154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
